Search

Novo Nordisk A-S (Class B)

Închisă

341.35 -0.28

Rezumat

Modificarea prețului

24h

Curent

Minim

340.8

Maxim

343.3

Indicatori cheie

By Trading Economics

Venit

-2.5B

27B

Vânzări

-1.2B

77B

P/E

Medie Sector

14.432

37.461

EPS

5.96

Randament dividend

3.4

Marjă de profit

34.484

Angajați

78,387

EBITDA

44B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+9.53% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.40%

2.33%

Următoarele câștiguri

5 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

138B

1.5T

Deschiderea anterioară

341.63

Închiderea anterioară

341.35

Novo Nordisk A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 oct. 2025, 10:26 UTC

Principalele dinamici ale pieței

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

17 oct. 2025, 10:25 UTC

Principalele dinamici ale pieței

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 oct. 2025, 15:36 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 oct. 2025, 13:27 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

9 oct. 2025, 10:49 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

22 oct. 2025, 10:45 UTC

Câștiguri

AI Stocks Aren't the Only Market Play. How -2-

22 oct. 2025, 10:45 UTC

Câștiguri

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

17 oct. 2025, 10:10 UTC

Principalele dinamici ale pieței

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 oct. 2025, 12:33 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 oct. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 oct. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 oct. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

10 oct. 2025, 16:19 UTC

Achiziții, Fuziuni, Preluări

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 oct. 2025, 13:03 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

9 oct. 2025, 15:17 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

9 oct. 2025, 11:31 UTC

Achiziții, Fuziuni, Preluări

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

9 oct. 2025, 10:34 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

9 oct. 2025, 10:07 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

9 oct. 2025, 10:05 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

9 oct. 2025, 10:04 UTC

Achiziții, Fuziuni, Preluări

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

9 oct. 2025, 10:03 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

9 oct. 2025, 10:01 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

7 oct. 2025, 09:15 UTC

Market Talk

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

1 oct. 2025, 09:05 UTC

Acțiuni populare

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sept. 2025, 12:04 UTC

Market Talk

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 sept. 2025, 13:43 UTC

Achiziții, Fuziuni, Preluări

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sept. 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18 sept. 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sept. 2025, 08:55 UTC

Acțiuni populare

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

9.53% sus

Prognoză pe 12 luni

Medie 1,162.73 DKK  9.53%

Maxim 1,550 DKK

Minim 720 DKK

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

7

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat